[The future of antibody fragments, made of a single immunoglobulin domain].
Monoclonal antibodies are now established as key therapeutics for a range of diseases including cancer and auto-immunity. However, despite important improvements, these molecules still face several serious limitations including production costs and tumor penetration. A new class of antibody fragments, made of a single immunoglobulin domain, is emerging as an exciting alternative. This review describes the outstanding properties and the first achievements of these domain antibodies.
Chames
Patrick
P
Anticorps thérapeutiques et immunociblage, Inserm U624, GDR 3260, 163, avenue de Luminy, 13288 Marseille Cedex 09, France. patrick.chames@inserm.fr
Baty
Daniel
D
D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D015195:Drug Design; D005544:Forecasting; D006801:Humans; D051379:Mice; D008958:Models, Molecular; D049329:Nanostructures; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology; D015202:Protein Engineering; D057127:Single-Chain Antibodies / Q000276:immunology* / Q000627:therapeutic use
D057127:Single-Chain Antibodies